Capture ELISA and in vitro cell binding assay for the detection of antibodies to human papillomavirus type 6b virus-like particles in patients with anogenital warts

Shiwen Peng, Yingmei Qi, Neil Christensen, Kylie Hengst, Lynn Kennedy, Ian H. Frazer, Robert W. Tindle

Research output: Contribution to journalArticle


To investigate human papillomavirus (HPV) virus-like particle (VLP)-specific antibody responses among anogenital warts patients, a VLP-based capture ELISA was established. Twenty-six percent (35/134) of control subjects and 50.0% (39/78) of patients with current anogenital warts showed IgG seropositivity to HPV 6b VLPs. HPV 6b VLP-specific antibody responses recognised native VLPs only, and had no cross-reaction with HPV type 16 VLPs. No differences in reactivity were observed between L1 and L1 + L2 VLPs, suggesting that L2 contributes little to the total immunogenicity of the papillomavirus virion. A VLP-cell binding assay was also established. Some sera from patients with anogenital warts specifically inhibited VLP binding to the surface of epithelial cells, suggesting that these antibodies might be functionally neutralising. These data show that serological responses to HPV 6b VLPs were induced among some but not all patients with anogenital warts, and give a proportional estimate of infection in the community.

Original languageEnglish (US)
Pages (from-to)418-422
Number of pages5
Issue number4
StatePublished - Jan 1 1999



  • Genital warts
  • Human papillomavirus
  • Serology
  • VLP

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this